DEVELOPMENT OF NOVEL, HIGHLY MTORC1 SELECTIVE INHIBITORS FOR THE TREATMENT OF TUBEROUS SCLEROSIS.

$472,028FY2019Department of the ArmyDOD

Aeovian Pharmaceuticals, Inc.

Investigators